Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips

Immunic, Inc. (IMUX),a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Barclay "Buck" A.Phillips, an established life sciences executive, investor and entrepreneur, to its Board of Directors, effectiveNovember 14, 2019...
Read Full Article